Development pipeline

Actelion's focus on high unmet medical needs

PhaseProduct/ CompoundIndicationStudyResults expected

IV

Bosentan

Combination bosentan & sildenafil in PAH

COMPASS-2

IV

Miglustat

Type 1 Gaucher disease patients switched from ERT to miglustat

MAINTENANCE

H2 2010

III

Almorexant

Insomnia 

RESTORA

-

III

Clazosentan

Prevention of vasospasm-related morbidity / mortality post aneurysmal subarachnoid hemorrage (SAH)

CONSCIOUS-2

CONSCIOUS-3

H2 2010

2011

III

Macitentan

Pulmonary arterial hypertension

SERAPHIN

H2 2011 

III

Olesoxime*

Amyotrophic Lateral Sclerosis

H2 2011

III

Selexipag 

Pulmonary arterial hypertension

GRIPHON

-

II

Antibiotic

Anti-infective

-  

II

CRTH2 antagonist

Asthma

II

CRTH2 antagonist

Allergic rhinitis

H2 2011 

II

Macitentan

Idiopathic pulmonary fibrosis (IPF)

MUSIC

H2 2011

II

S1P1 agonist  

Multiple sclerosis 

H2 2011

II

S1P1 agonist

Plaque psoriasis

-

I

Cardiovascular

Cardiovascular 

* Option to acquire

 
 
 
 

Top of page    Print pageSend this page to a friendBookmark with del.icio.usBookmark with diggBookmark with MISTER WONG

 

Lab Technician, Drug Discovery Pharmacology & Preclinical Development  

 

"One day the results of my work could help patients who currently have no treatment of their disease."